Terms: = Skin cancer AND PRKAR1A, DKFZp779L0468, 5573, ENSG00000108946, PRKAR1, P10644, CNC1, PKR1, MGC17251, PPNAD1, TSE1, CNC, CAR AND Treatment
106 results:
1. New hopes for the breast cancer treatment: perspectives on the oncolytic virus therapy.
Chowaniec H; Ślubowska A; Mroczek M; Borowczyk M; Braszka M; Dworacki G; Dobosz P; Wichtowski M
Front Immunol; 2024; 15():1375433. PubMed ID: 38576614
[TBL] [Abstract] [Full Text] [Related]
2. Adoptive cell therapy for solid tumors beyond car-T: Current challenges and emerging therapeutic advances.
Zhang T; Tai Z; Miao F; Zhang X; Li J; Zhu Q; Wei H; Chen Z
J Control Release; 2024 Apr; 368():372-396. PubMed ID: 38408567
[TBL] [Abstract] [Full Text] [Related]
3. Breakthrough in Blastic Plasmacytoid Dendritic Cell Neoplasm cancer Therapy Owing to Precision Targeting of CD123.
Zanotta S; Galati D; De Filippi R; Pinto A
Int J Mol Sci; 2024 Jan; 25(3):. PubMed ID: 38338733
[TBL] [Abstract] [Full Text] [Related]
4. GPRC5D as a novel target for the treatment of multiple myeloma: a narrative review.
Rodriguez-Otero P; van de Donk NWCJ; Pillarisetti K; Cornax I; Vishwamitra D; Gray K; Hilder B; Tolbert J; Renaud T; Masterson T; Heuck C; Kane C; Verona R; Moreau P; Bahlis N; Chari A
Blood Cancer J; 2024 Feb; 14(1):24. PubMed ID: 38307865
[TBL] [Abstract] [Full Text] [Related]
5. Allogeneic transplantation and cellular therapies in cutaneous T-cell lymphoma.
Goyal A; Foss F
Expert Rev Anticancer Ther; 2024; 24(1-2):41-58. PubMed ID: 38224371
[TBL] [Abstract] [Full Text] [Related]
6. Nanocatalytic Anti-Tumor Immune Regulation.
Li M; Jiang H; Hu P; Shi J
Angew Chem Int Ed Engl; 2024 Mar; 63(13):e202316606. PubMed ID: 38212843
[TBL] [Abstract] [Full Text] [Related]
7. Revolutionizing cancer treatment: comprehensive insights into immunotherapeutic strategies.
Raghani NR; Chorawala MR; Mahadik M; Patel RB; Prajapati BG; Parekh PS
Med Oncol; 2024 Jan; 41(2):51. PubMed ID: 38195781
[TBL] [Abstract] [Full Text] [Related]
8. Immunotherapy targeting B cells and long-lived plasma cells effectively eliminates pre-existing donor-specific allo-antibodies.
Zhang Z; Markmann C; Yu M; Agarwal D; Rostami S; Wang W; Liu C; Zhao H; Ochoa T; Parvathaneni K; Xu X; Li E; Gonzalez V; Khadka R; Hoffmann J; Knox JJ; Scholler J; Marcellus B; Allman D; Fraietta JA; Samelson-Jones B; Milone MC; Monos D; Garfall AL; Naji A; Bhoj VG
Cell Rep Med; 2023 Dec; 4(12):101336. PubMed ID: 38118406
[TBL] [Abstract] [Full Text] [Related]
9. Harnessing immunotherapy for brain metastases: insights into tumor-brain microenvironment interactions and emerging treatment modalities.
Zhou D; Gong Z; Wu D; Ma C; Hou L; Niu X; Xu T
J Hematol Oncol; 2023 Dec; 16(1):121. PubMed ID: 38104104
[TBL] [Abstract] [Full Text] [Related]
10. car NK Cell Therapy for the treatment of Metastatic Melanoma: Potential & Prospects.
Hibler W; Merlino G; Yu Y
Cells; 2023 Nov; 12(23):. PubMed ID: 38067178
[TBL] [Abstract] [Full Text] [Related]
11. Development and pharmacokinetic assessment of a fully canine anti-PD-1 monoclonal antibody for comparative translational research in dogs with spontaneous tumors.
Yoshimoto S; Chester N; Xiong A; Radaelli E; Wang H; Brillantes M; Gulendran G; Glassman P; Siegel DL; Mason NJ
MAbs; 2023; 15(1):2287250. PubMed ID: 38047502
[TBL] [Abstract] [Full Text] [Related]
12. CSPG4 car-redirected Cytokine Induced Killer lymphocytes (CIK) as effective cellular immunotherapy for HLA class I defective melanoma.
Giraudo L; Cattaneo G; Gammaitoni L; Iaia I; Donini C; Massa A; Centomo ML; Basiricò M; Vigna E; Pisacane A; Picciotto F; Berrino E; Marchiò C; Merlini A; Paruzzo L; Poletto S; Caravelli D; Biolato AM; Bortolot V; Landoni E; Ventin M; Ferrone CR; Aglietta M; Dotti G; Leuci V; Carnevale-Schianca F; Sangiolo D
J Exp Clin Cancer Res; 2023 Nov; 42(1):310. PubMed ID: 37993874
[TBL] [Abstract] [Full Text] [Related]
13. Combining CSPG4-car and CD20-CCR for treatment of metastatic melanoma.
Teppert K; Winter N; Herbel V; Brandes C; Lennartz S; Engert F; Kaiser A; Schaser T; Lock D
Front Immunol; 2023; 14():1178060. PubMed ID: 37901209
[TBL] [Abstract] [Full Text] [Related]
14. Brave new world-new and emerging treatments for gastric cancer.
Lynch E; Duffy AG; Kelly RJ
Chin Clin Oncol; 2023 Oct; 12(5):54. PubMed ID: 37691344
[TBL] [Abstract] [Full Text] [Related]
15. Pre-clinical validation of a pan-cancer car-T cell immunotherapy targeting nfP2X7.
Bandara V; Foeng J; Gundsambuu B; Norton TS; Napoli S; McPeake DJ; Tyllis TS; Rohani-Rad E; Abbott C; Mills SJ; Tan LY; Thompson EJ; Willet VM; Nikitaras VJ; Zheng J; Comerford I; Johnson A; Coombs J; Oehler MK; Ricciardelli C; Cowin AJ; Bonder CS; Jensen M; Sadlon TJ; McColl SR; Barry SC
Nat Commun; 2023 Sep; 14(1):5546. PubMed ID: 37684239
[TBL] [Abstract] [Full Text] [Related]
16. T Cells Expressing car Equipped With Extracellular Domain of BTLA Are Effective Against HVEM-over-expressing Melanoma Cell Lines.
Kim Y; Kim JE; Lee DY; Choi JU; Park JS; Lee HK; Choi SU; Park S; Park CH
Anticancer Res; 2023 Aug; 43(8):3419-3427. PubMed ID: 37500142
[TBL] [Abstract] [Full Text] [Related]
17. Targeting Solid cancers with a cancer-Specific Monoclonal Antibody to Surface Expressed Aberrantly O-glycosylated Proteins.
Aasted MKM; Groen AC; Keane JT; Dabelsteen S; Tan E; Schnabel J; Liu F; Lewis HS; Theodoropulos C; Posey AD; Wandall HH
Mol Cancer Ther; 2023 Oct; 22(10):1204-1214. PubMed ID: 37451822
[TBL] [Abstract] [Full Text] [Related]
18. Host Interactions with Engineered T-cell Micropharmacies.
Bourne CM; Wallisch P; Dacek MM; Gardner TJ; Pierre S; Vogt K; Corless BC; Bah MA; Romero-Pichardo JE; Charles A; Kurtz KG; Tan DS; Scheinberg DA
Cancer Immunol Res; 2023 Sep; 11(9):1253-1265. PubMed ID: 37379366
[TBL] [Abstract] [Full Text] [Related]
19. Phase I Trial of Autologous RNA-electroporated cMET-directed car T Cells Administered Intravenously in Patients with Melanoma and Breast carcinoma.
Shah PD; Huang AC; Xu X; Orlowski R; Amaravadi RK; Schuchter LM; Zhang P; Tchou J; Matlawski T; Cervini A; Shea J; Gilmore J; Lledo L; Dengel K; Marshall A; Wherry EJ; Linette GP; Brennan A; Gonzalez V; Kulikovskaya I; Lacey SF; Plesa G; June CH; Vonderheide RH; Mitchell TC
Cancer Res Commun; 2023 May; 3(5):821-829. PubMed ID: 37377890
[TBL] [Abstract] [Full Text] [Related]
20. Direct In Vivo Activation of T Cells with Nanosized Immunofilaments Inhibits Tumor Growth and Metastasis.
Weiss L; Weiden J; Dölen Y; Grad EM; van Dinther EAW; Schluck M; Eggermont LJ; van Mierlo G; Gileadi U; Bartoló-Ibars A; Raavé R; Gorris MAJ; Maassen L; Verrijp K; Valente M; Deplancke B; Verdoes M; Benitez-Ribas D; Heskamp S; van Spriel AB; Figdor CG; Hammink R
ACS Nano; 2023 Jul; 17(13):12101-12117. PubMed ID: 37338806
[TBL] [Abstract] [Full Text] [Related]
[Next]
